2015
DOI: 10.4103/1110-1067.164726
|View full text |Cite
|
Sign up to set email alerts
|

The SALL4 gene in acute leukemias

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 1 publication
0
1
0
Order By: Relevance
“…It was also noticed that AML cases co-aberrantly expressing either CD7 or CD56 revealed higher median expression levels of SALL4 gene (47.31 and 44.66; respectively) compared to cases neither expressing CD7 nor CD56 (18.46 and 17.96; respectively) However, these findings were of no statistical significance. Abo-Elwafa et al [29] had a consistent result as they stated that there was no statistically significant difference between the expression level of CD markers and SALL4 mRNA in AML cases. Comparably, Farawela et al [28] discovered that although SALL4 expression in AML patients with positive CD34 expression increased more than in those with negative CD34 expression (median 2.608-fold increment), the difference was not statistically significant.…”
Section: Discussionmentioning
confidence: 78%
“…It was also noticed that AML cases co-aberrantly expressing either CD7 or CD56 revealed higher median expression levels of SALL4 gene (47.31 and 44.66; respectively) compared to cases neither expressing CD7 nor CD56 (18.46 and 17.96; respectively) However, these findings were of no statistical significance. Abo-Elwafa et al [29] had a consistent result as they stated that there was no statistically significant difference between the expression level of CD markers and SALL4 mRNA in AML cases. Comparably, Farawela et al [28] discovered that although SALL4 expression in AML patients with positive CD34 expression increased more than in those with negative CD34 expression (median 2.608-fold increment), the difference was not statistically significant.…”
Section: Discussionmentioning
confidence: 78%
“…In patients with MDS, a group of preleukemic hematologic disorders, a high level of SALL4 expression is detected and correlated with high-risk patients with poor survival [58,59]. In AML cases, our group and others have reported that SALL4 mRNA or proteins are aberrantly expressed in various AML subtypes (ranging from M1 to M5, the French-American-British [FAB] classification), and SALL4 expression is involved in chromosomal instability and associated with disease status and drug treatments [59][60][61][62][63][64][65]. SALL4 expression is found significantly higher in AML patients with complex karyotype (equal to or more than three aberrant karyotypes) than that in MDS patients with normal karyotype [63].…”
Section: Sall4 Is Aberrantly Expressed In Human Leukemiasmentioning
confidence: 90%